Invega Sustenna Injection
Product Images NDC 50458-562

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Invega Sustenna (NDC 50458-562). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Invega 01)

This is a description for a prefilled syringe with two different gauges: 2Gx14" and 23Gx1". The syringe has a gray hub and a blue hub and is labeled with the letter "A". It also comes with a tip cap.*

FDA Label Image

Figure (Invega 02)

FDA Label Image

Figure (Invega 03)

FDA Label Image

Figure (Invega 04)

FDA Label Image

Figure (Invega 05)

FDA Label Image

Figure (Invega 06)

FDA Label Image

H1 (Invega 07)

FDA Label Image

H2 (Invega 08)

FDA Label Image

H3 (Invega 09)

FDA Label Image

Chemical Structure (Invega 10)

FDA Label Image

Figure 1 (Invega 11)

This appears to be a list of drug interactions and pharmacokinetic parameters. Specifically, it mentions a CYP2D6 inhibitor called Paroxetine and a CYP3A4 inducer called Carbamazepine, both of which can affect how drugs are metabolized in the body. It also lists Divalproex Sodium ER and mentions pharmacokinetic parameters called AuC and Cmax, which are measures of drug exposure and peak concentration in the blood, respectively. The text also references Fold Change and 90% Confidence Intervals, which may be related to the pharmacokinetic parameters. Overall, this may be information related to drug development or dosing considerations.*

FDA Label Image

Figure 2 (Invega 12)

This is a graphic representation of the effect of intrinsic factors, such as renal or hepatic impairment, age and gender, on the pharmacokinetics of the medication paliperidone. The chart displays fold changes and 90% confidence intervals in paliperidone's area under the concentration-time curve (AUC) and maximum concentration (Cmax) for different subpopulations compared to the 'normal' or reference group. The higher or lower AUC/Cmax values indicate differences in the drug's absorption, distribution, and elimination processes, which can affect its efficacy and toxicity.*

FDA Label Image

Figure 3 (Invega 13)

This appears to be a chart or a graph showing the estimated percentage of subjects with relapse over time. The X-axis shows the number of days since randomization, while the Y-axis shows the estimated percentage of subjects with relapse. There are two groups represented in this chart - the placebo group and the group treated with something called INVE GASUSTE NN. The median time to relapse in the placebo group is stated to be 163 days. Beyond this, it is not possible to interpret the information provided.*

FDA Label Image

Figure 4 (Invega 13a)

FDA Label Image

Figure 4 (Invega 14)

FDA Label Image

Principal Display Panel (39 mg Syringe Carton)

This appears to be a package insert for a medication called Invega Sustenna. The medication is administered via intramuscular injection using a single-dose prefilled syringe. Each syringe contains 39 mg/0.25 mL of paliperidone palmitate, an extended-release injectable suspension. The medication is only to be administered by a healthcare professional. The package insert includes instructions for storage and use.*

FDA Label Image

Principal Display Panel (78 mg Syringe Carton)

This text seems to describe a medication named INVEGA SUSTENNA. It comes in a single dose prefilled syringe that has to be used in its entirety and contains 78mg/0.5mL. The injection is intended for intramuscular use by a healthcare professional. The accompanying package insert needs to be followed for proper usage. The syringe comes with two needles, one 1/2 inch safety needle and another 1-inch safety needle. The medication needs to be shaken before use and should be stored in a dry place between 77°F and 85°F. The obtains a few technical and non-readable symbols; however, they do not affect the overall meaning of the text.*

FDA Label Image

Principal Display Panel (117 mg Syringe Carton)

This is a product description of Invega Sustenna, a single-dose profiled syringe for intramuscular injection containing paliperidone palmitate. It is a 117 mg/0.75 mL suspension used to treat some mental disorders. The package includes a single-dose prefilled syringe, two needles, and a saline diluent. It should be administered by healthcare professionals. It should be stored at room temperature. The rest of the text appears to be gibberish and is not readable.*

FDA Label Image

Principal Display Panel (156 mg Syringe Carton)

FDA Label Image

Principal Display Panel (234 mg Syringe Carton)

This is a prescription medication called Invega Sustenna with the active ingredient being paliperidone. It is administered through an intramuscular injection using a single-dose prefilled syringe containing 234mg of the active ingredient. The medication is stored at room temperature and must be shaken before use. The medication is indicated only for use with its entire contents for the treatment of certain mental and mood disorders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.